This clinical trial is focused on studying a kidney disease called Primary IgA Nephropathy, which is a condition where the immune system causes damage to the kidneys. The study is testing a new treatment called RO7434656, which is an antisense inhibitor of complement factor B. This treatment is designed to help reduce the progression of the disease in patients who are at high risk. The trial will compare the effects of RO7434656 with a placebo to see how well it works in reducing protein levels in the urine, which is a sign of kidney damage.

Participants in the study will receive either the RO7434656 treatment or a placebo through injections. The study will last for several weeks, during which time the participants’ health and kidney function will be closely monitored. The main goal is to see if the treatment can lower the amount of protein in the urine, which is measured by the urine protein-to-creatinine ratio (UPCR). This will help determine if the treatment is effective in slowing down the disease.

Throughout the study, participants will have regular check-ups to assess their kidney function and overall health. The study will also look at other factors, such as changes in fatigue levels and any side effects that may occur. By the end of the study, researchers hope to gather enough information to understand the safety and effectiveness of RO7434656 in treating Primary IgA Nephropathy.